Bio-Rad Laboratories (BIO) Net Equity Issued and Repurchased (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Net Equity Issued and Repurchased for 18 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed 0.0% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $15.2 million, a 16.94% decrease from a year earlier, with the FY2019 full-year figure at $13.1 million, down 7.22% from the prior year.
• Net Equity Issued and Repurchased was $4.2 million for Q2 2026 at Bio-Rad Laboratories, up from $3.4 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $7.6 million in Q3 2022 and troughed at $3.4 million in Q3 2025.
• A 5-year average of $4.7 million and a median of $4.4 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• Across the five-year window, Net Equity Issued and Repurchased soared 148.84% in 2022 and sank 33.33% in 2025, its largest moves.
• Over 5 years, Net Equity Issued and Repurchased stood at $7.6 million in 2022, then tumbled by 32.3% to $5.1 million in 2023, then slipped by 0.22% to $5.1 million in 2024, then plunged by 33.33% to $3.4 million in 2025, then advanced by 23.53% to $4.2 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $4.2 million (Q2 2026), $3.4 million (Q1 2026), and $3.4 million (Q3 2025), per Business Quant data.